Novo took part in the first round for VectivBio, a short bowel syndrome treatment developer launched out of genetic disease drug developer Therachon.

Switzerland-based rare disease therapy developer VectivBio launched on Tuesday with $35m in capital from investors including pharmaceutical firm Novo. The corporate joined Inserm Transfer Initiative, the investment arm of research institute Inserm, as well as government-owned investment bank BPIfrance, Cowen Healthcare Investments, Tekla Healthcare Investors, Versant Ventures and OrbiMed in the round. VectivBio is developing…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.